| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 340.5 | 207.6 |
| Profit before tax | 120.3 | 15.2 |
| Net income | 126.8 | 19.7 |
| EPS (diluted, $ a share) | $1.01 | $0.16 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +544.6% |
|---|---|
| Revenue, year on year | +64.0% |
| Operating margin | 33.7% |
10-Q filed with the SEC, NASDAQ: CORT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Corcept Therapeutics Inc: key numbers
- Share price
- $69.22Close, Nov 16
- Market cap
- $7.58B
- Shares outstanding
- 109.44MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Corcept Therapeutics Inc
All →Corcept Therapeutics Director Daniel N. Swisher Jr. Sells $111K of Stock
Daniel N. Swisher Jr., Director, sold 1,500 shares of Corcept Therapeutics Inc at $74.07 a share, worth $111K in total on Nov 10, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $111K
- Shares
- 1,500
- Price
- $74.07
- Role
- Director
- Holding change
- -100.0%
- Trade date
- Nov 10, 2026
Corcept Therapeutics Insider Sean Maduck Sells $2.05M of Stock
Sean Maduck sold 25,000 shares of Corcept Therapeutics Inc at $81.42 to $82.68 a share (average $81.85) in 3 transactions, worth $2.05M in total between Nov 2, 2026 and Nov 3, 2026. Shares held after the trade: 9,938 (-31.4%).
- Value
- $2.05M
- Shares
- 25,000
- Average price
- $81.85
- Holding change
- -31.4%
- Trade date
- Nov 2, 2026 to Nov 3, 2026
Corcept Therapeutics President, Oncology Roberto Wandenkolk Vieira Sells $674K of Stock
Roberto Wandenkolk Vieira, President, Oncology, sold 8,333 shares of Corcept Therapeutics Inc at $80.73 to $81.52 a share (average $80.89) in 2 transactions, worth $674K in total on Nov 2, 2026. Shares held after the trade: 3,946 (-29.8%).
- Value
- $674K
- Shares
- 8,333
- Average price
- $80.89
- Role
- President, Oncology
- Holding change
- -29.8%
- Trade date
- Nov 2, 2026
Corcept Therapeutics Financial Results
Corcept Therapeutics reported Q3 2026 revenue of $340.5 million, a 64% increase year-over-year, driven by strong growth in Korlym and the rapid uptake of Lifyorli in ovarian cancer. Net income rose significantly to $126.8 million, or $1.01 per diluted share, while the company reiterated its full-year 2026 revenue guidance of $1.1 billion to $1.2 billion.
- Term
- Q3 2026
“Awareness of the importance of diagnosing and treating patients with Cushing’s syndrome is steadily increasing and is driving the growth of our endocrinology business. Lifyorli’s uptake in ovarian cancer has been both very rapid and broad. Since its April 1st launch, more than 2,300 patients have received the medication. More than 1,700 physicians have prescribed it. We expect continued growth in both businesses and have reiterated our 2026 revenue guidance of $1.1 – $1.2 billion.”
Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer
“The ADA and EASD consensus statement is an important advance for the many patients whose difficult-to-control hyperglycemia is a manifestation of undiagnosed Cushing’s syndrome. Optimal care starts with screening and a correct diagnosis. The ADA/EASD report also identifies mifepristone as a potential treatment, citing the positive results of our CATALYST trial.”
Bill Guyer, PharmD, Corcept’s Chief Development Officer
Corcept Therapeutics Director James N. Wilson Sells $1.15M of Stock
James N. Wilson, Director, sold 10,000 shares of Corcept Therapeutics Inc at $114.48 to $116.30 a share (average $114.81) in 3 transactions, worth $1.15M in total on Oct 15, 2026. Shares held after the trade: 1,054,543 (-0.0%).
- Value
- $1.15M
- Shares
- 10,000
- Average price
- $114.81
- Role
- Director
- Holding change
- -0.0%
- Trade date
- Oct 15, 2026
Corcept Therapeutics President, Oncology Roberto Wandenkolk Vieira Sells $967K of Stock
Roberto Wandenkolk Vieira, President, Oncology, sold 8,333 shares of Corcept Therapeutics Inc at $114.52 to $116.58 a share (average $116.10) in 3 transactions, worth $967K in total on Oct 2, 2026. Shares held after the trade: 3,946 (-56.6%).
- Value
- $967K
- Shares
- 8,333
- Average price
- $116.10
- Role
- President, Oncology
- Holding change
- -56.6%
- Trade date
- Oct 2, 2026